Neuphoria Therapeutics (NEUP) Accumulated Expenses (2021 - 2026)

Neuphoria Therapeutics (NEUP) has 6 years of Accumulated Expenses data on file, last reported at $10598.0 in Q1 2026.

• Quarterly Accumulated Expenses fell 97.33% year-over-year to $10598.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10598.0 (down 97.33% YoY) and the FY2025 annual result came in at $3.0 million, up 354.66% from the prior year.
• Accumulated Expenses declined to $10598.0 in Q1 2026 per NEUP's latest filing, from $2.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $3.0 million in Q2 2025 and bottomed at $10598.0 in Q1 2026.
• The 5-year median for Accumulated Expenses is $721369.5 (2024), against an average of $971441.4.
• The widest annual swing landed in 2025, when Accumulated Expenses jumped 354.66%; it then slumped 97.33% in 2026.
• Tracing NEUP's Accumulated Expenses over 5 years: stood at $293183.0 in 2022, then surged by 227.8% to $961060.9 in 2023, then decreased by 17.4% to $793881.0 in 2024, then jumped by 160.19% to $2.1 million in 2025, then tumbled by 99.49% to $10598.0 in 2026.
• Per Business Quant, the three latest NEUP Accumulated Expenses figures stand at $10598.0 (Q1 2026), $2.1 million (Q4 2025), and $497667.0 (Q3 2025).

Peer Comparison